SABA reliever use predicts both current control and future risk of exacerbations in patients with moderate to severe COPD, Australian research confirms. Writing in BMC Pulmonary Medicine Christine Jenkins and colleagues from The George Institute of Global Health noted that debate existed around which endpoints most sensitively reflected day-to-day variation in COPD symptoms. “Ideally, outcomes in COPD ...
Already a member?
Enter your email to keep reading.